A Comparative Study on CT-guided Radiofrequency Ablation and Targeted Therapy: Intervention Efficacy and Survival Rates in Lung Cancer Patients

被引：0
作者：
Zhao, Tianyu [1 ]
Zhang, Chunjing [1 ]
Dai, Hang [2 ]
Li, Jingyu [1 ]
Hao, Liguo [1 ]
Liu, Yanan [1 ]
机构：
[1] Qiqihar Med Univ, Med Technol Dept, Qiqihar 161006, Heilongjiang, Peoples R China
[2] Qiqihar Med Univ, Foreign Language Dept, 333,Bukui North St, Qiqihar 161006, Heilongjiang, Peoples R China
来源：
CURRENT MEDICAL IMAGING | 2025年 / 21卷
关键词：
Lung cancer; Radiofrequency ablation; Targeted therapy; Clinical efficacy; Immune response; Safety; Survival time; MANAGEMENT;
D O I：
10.2174/0115734056311827241211092432
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Objective The study aimed to evaluate the clinical efficacy of CT-guided radiofrequency ablation in conjunction with targeted therapy in lung cancer patients.Methods We retrospectively analyzed 80 lung cancer patients. They were stratified into the Observation Group (OG; n=40, treated with CT-guided radiofrequency ablation in conjunction with targeted therapy) and the Control Group (CG; n=40, treated solely with targeted therapy).Results The Overall Response Rate (ORR) and Disease Control Rate (DCR) in the OG group (70.00%, 95.00%) were significantly higher than those in the CG group (57.50%, 87.50%). After 6 weeks of treatment, the OG group had significantly lower levels of SCC, CEA, and CA125, higher CD4+ levels, and lower CD8+ levels, compared to the CG group. The 24-month follow-up survival rate of the OG group (47.50%) was significantly higher than that of the CG group (27.50%).Conclusion CT-guided radiofrequency ablation and targeted therapy have been proven effective in treating lung cancer.
引用
收藏
页数：9
相关论文
共 22 条
[1]   Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series [J].
Ahmed, Tahreem ;
Vial, Macarena R. ;
Ost, David ;
Stewart, John ;
Hasan, Muhammad A. ;
Grosu, Horiana B. .
LUNG CANCER, 2018, 122 :220-223
[2]   Ramucirumab in the treatment of non-small cell lung cancer [J].
Arrieta, Oscar ;
Lucia Zatarain-Barron, Zyanya ;
Cardona, Andres F. ;
Carmona, Amir ;
Lopez-Mejia, Mariana .
EXPERT OPINION ON DRUG SAFETY, 2017, 16 (05) :637-644
[3]   Non-small cell lung cancer in China [J].
Chen, Peixin ;
Liu, Yunhuan ;
Wen, Yaokai ;
Zhou, Caicun .
CANCER COMMUNICATIONS, 2022, 42 (10) :937-970
[4]   Surgical resection, radiotherapy and percutaneous thermal ablation for treatment of stage 1 non-small cell lung cancer: protocol for a systematic review and network meta-analysis [J].
Chockalingam, Arun ;
Konstantinidis, Menelaos ;
Koo, Brandon ;
Moon, John Timothy ;
Tran, Andrew ;
Nourouzpour, Sahar ;
Lawson, Emily ;
Fox, Kathleen ;
Habibollahi, Peiman ;
Odisio, Bruno ;
Loya, Mohammed ;
Bassir, Ali ;
Nezami, Nariman .
BMJ OPEN, 2022, 12 (06)
[5]   Targeting KRAS mutant lung cancer: light at the end of the tunnel [J].
Drosten, Matthias ;
Barbacid, Mariano .
MOLECULAR ONCOLOGY, 2022, 16 (05) :1057-1071
[6]   Management of Brain Metastases in Non-Small-Cell Lung Cancer [J].
Ernani, Vinicius ;
Stinchcombe, Thomas E. .
JOURNAL OF ONCOLOGY PRACTICE, 2019, 15 (11) :563-+
[7]   LncRNAs in Non-Small-Cell Lung Cancer [J].
Ginn, Lucy ;
Shi, Lei ;
La Montagna, Manuela ;
Garofalo, Michela .
NON-CODING RNA, 2020, 6 (03)
[8]   The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) [J].
Golding, Brandon ;
Luu, Anita ;
Jones, Robert ;
Viloria-Petit, Alicia M. .
MOLECULAR CANCER, 2018, 17
[9]   Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation [J].
Hattori, Sou ;
Okauchi, Shinichiro ;
Sasatani, Yuika ;
Ohara, Gen ;
Miyazaki, Kunihiko ;
Sato, Shinya ;
Kodama, Takahide ;
Shiozawa, Toshihiro ;
Satoh, Hiroaki ;
Hizawa, Nobuyuki .
ANTICANCER RESEARCH, 2022, 42 (09) :4589-4595
[10]   Recent advances in the management of lung cancer [J].
Jones, Gavin S. ;
Baldwin, David R. .
CLINICAL MEDICINE, 2018, 18 (02) :S41-S46
123